Despite market volatility, platform biotechnology, especially in modalities like mRNA, gene editing, and targeted protein degradation has seen renewed investor confidence.
The 2025 talent reports clearly communicate that the shortage of digital, AI and data-science skills in life sciences is no longer a peripheral issue; it’s central to operational effectiveness.
With more than 140 advanced therapies approved or in development, the business models of commercialization, manufacturing scale, and regulatory strategy must align.
The FDA’s ISTAND Pilot Program has been elevated as a permanent qualification program to be qualified as Drug Development Tools (DDTs).
The FDA’s “Roadmap to Reducing Animal Testing” signals a shift.
Let’s connect your expertise with audiences that matter most.
Global Reach • Based in Boston, Massachusetts, USA